FDA approves Pfizer advanced breast cancer med

Oct 16, 2018

The U.S. Food and Drug Administration has approved talazoparib, Pfizer's drug for an advanced form of breast cancer tied to an inherited gene mutation.

The drug is part of a class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

Talazoparib is a once-daily pill that Pfizer acquired during its acquisition of Medivation in 2016. The drug is indicated for breast cancer triggered by mutation of BRCA genes, which accounts for 25 – 30 percent of hereditary breast cancers and 5 – 10 percent of all breast cancers.

Read the Reuters report

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments